JP2010500565A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500565A5 JP2010500565A5 JP2009523844A JP2009523844A JP2010500565A5 JP 2010500565 A5 JP2010500565 A5 JP 2010500565A5 JP 2009523844 A JP2009523844 A JP 2009523844A JP 2009523844 A JP2009523844 A JP 2009523844A JP 2010500565 A5 JP2010500565 A5 JP 2010500565A5
- Authority
- JP
- Japan
- Prior art keywords
- markers
- expression
- level
- predictive
- marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003550 marker Substances 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 42
- 230000007774 longterm Effects 0.000 claims description 23
- 230000004083 survival effect Effects 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 238000011269 treatment regimen Methods 0.000 claims description 9
- 239000013610 patient sample Substances 0.000 claims description 8
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 6
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 4
- 229960001467 bortezomib Drugs 0.000 claims description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000003862 glucocorticoid Substances 0.000 claims description 4
- 239000003207 proteasome inhibitor Substances 0.000 claims description 4
- 239000000523 sample Substances 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 238000007619 statistical method Methods 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83676406P | 2006-08-10 | 2006-08-10 | |
| US60/836,764 | 2006-08-10 | ||
| PCT/US2007/017716 WO2008021183A2 (en) | 2006-08-10 | 2007-08-09 | For the identification, assessment, and treatment of patients with cancer therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010500565A JP2010500565A (ja) | 2010-01-07 |
| JP2010500565A5 true JP2010500565A5 (enExample) | 2010-09-24 |
| JP5725711B2 JP5725711B2 (ja) | 2015-05-27 |
Family
ID=39082605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009523844A Active JP5725711B2 (ja) | 2006-08-10 | 2007-08-09 | 癌治療法を有する患者の同定、評価、および治療のための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9500656B2 (enExample) |
| EP (1) | EP2046973A4 (enExample) |
| JP (1) | JP5725711B2 (enExample) |
| AU (1) | AU2007284724B2 (enExample) |
| CA (1) | CA2660275A1 (enExample) |
| MX (1) | MX2009001489A (enExample) |
| WO (1) | WO2008021183A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009151967A1 (en) * | 2008-05-28 | 2009-12-17 | Georgia Tech Research Corporation | Metabolic biomarkers for ovarian cancer and methods of use thereof |
| WO2010019921A2 (en) * | 2008-08-15 | 2010-02-18 | The Regents Of The University Of California | Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia |
| WO2010107960A1 (en) * | 2009-03-17 | 2010-09-23 | Brody Jonathan R | Methods for assessing the efficacy of gemcitabine or ara-c treatment of cancer using human antigen r levels |
| AU2010237572B2 (en) * | 2009-04-17 | 2015-04-09 | University Health Network | Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof |
| EP2419540B1 (en) * | 2009-04-18 | 2017-05-17 | Merck Sharp & Dohme Corp. | Methods and gene expression signature for assessing ras pathway activity |
| US7615353B1 (en) * | 2009-07-06 | 2009-11-10 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
| US20120309640A1 (en) * | 2009-10-08 | 2012-12-06 | Torti Frank M | Diagnostic and Prognostic Markers for Cancer |
| NZ600268A (en) * | 2010-01-11 | 2014-08-29 | Genomic Health Inc | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
| WO2012024612A1 (en) * | 2010-08-20 | 2012-02-23 | Pangea Biosciences, Inc. | Cancer diagnostic and cancer therapeutic |
| WO2013023132A1 (en) | 2011-08-10 | 2013-02-14 | Wake Forest University Health Sciences | Diagnostic and prognostic markers for cancer |
| AU2012294493B2 (en) | 2011-08-11 | 2017-02-23 | Janssen Pharmaceutica Nv | Predictors for cancer treatment |
| WO2013112881A1 (en) | 2012-01-27 | 2013-08-01 | Thomas Jefferson University | Mct protein inhibitor-related prognostic and therapeutic methods |
| US12546782B2 (en) * | 2013-03-15 | 2026-02-10 | Mayo Foundation For Medical Education And Research | Identification and monitoring of monoclonal immunoglobulins related to monoclonal gammopathy by molecular mass with mass spectrometry |
| US10022372B2 (en) | 2013-04-19 | 2018-07-17 | Thomas Jefferson University | Caveolin-1 related methods for treating glioblastoma with temozolomide |
| MX369911B (es) | 2013-05-30 | 2019-11-26 | Genomic Health Inc | Método basado en expresión génica para clasificar pacientes con cãncer de riñón de acuerdo al riesgo de recurrencia. |
| US20150287143A1 (en) * | 2014-04-03 | 2015-10-08 | John Hancock Life Insurance Company (U.S.A.) | System and method for managing underwriting using a risk order approach |
| CA2944767C (en) | 2014-04-04 | 2022-07-12 | Mayo Foundation For Medical Education And Research | Isotyping immunoglobulins using accurate molecular mass |
| JP6675990B2 (ja) * | 2014-05-20 | 2020-04-08 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | 多発性骨髄腫の治療方法 |
| EP3175242A4 (en) | 2014-07-29 | 2017-12-27 | Mayo Foundation for Medical Education and Research | Quantifying monoclonal antibody therapeutics by lc-ms/ms |
| EP3353200A4 (en) | 2015-09-24 | 2019-06-26 | Mayo Foundation for Medical Education and Research | IDENTIFICATION OF FREE LIGHT CHAINS FROM IMMOBILIZED LOBULIN BY MASS SPECTROMETRY |
| US20180312928A1 (en) * | 2015-10-26 | 2018-11-01 | Cipherome | Method and system for selecting customized drug using genomic nucleotide sequence variation information and survival information of cancer patient |
| AU2017325022B2 (en) | 2016-09-07 | 2022-10-13 | Mayo Foundation For Medical Education And Research | Identification and monitoring of cleaved immunoglobulins by molecular mass |
| WO2018201083A1 (en) | 2017-04-28 | 2018-11-01 | University Of Southern California | System and method for predicting survival time |
| US11946937B2 (en) | 2017-09-13 | 2024-04-02 | Mayo Foundation For Medical Education And Research | Identification and monitoring of apoptosis inhibitor of macrophage |
| US12153052B2 (en) | 2017-09-13 | 2024-11-26 | Mayo Foundation For Medical Education And Research | Identification and monitoring of immunoglobulin J chains |
| CN110108878A (zh) * | 2019-05-30 | 2019-08-09 | 四川大学华西医院 | Eif2s1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05296999A (ja) * | 1992-04-24 | 1993-11-12 | Amano Pharmaceut Co Ltd | グルココルチコイドの効果判定マーカーとしてのヒトリポコルチンｉ及びその定量法 |
| JP2004248502A (ja) * | 2000-10-05 | 2004-09-09 | Takara Holdings Inc | 癌悪性度の評価方法 |
| KR20040111456A (ko) * | 2002-04-04 | 2004-12-31 | 이시하라 산교 가부시끼가이샤 | 데이터 해석 장치 및 방법 |
| ES2542328T3 (es) * | 2002-12-06 | 2015-08-04 | Millennium Pharmaceuticals, Inc. | Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma |
| US20040191782A1 (en) * | 2003-03-31 | 2004-09-30 | Yixin Wang | Colorectal cancer prognostics |
| US7741035B2 (en) * | 2004-05-21 | 2010-06-22 | Board Of Trustees Of The University Of Arkansas | Use of gene expression profiling to predict survival in cancer patient |
| ES2624863T3 (es) * | 2005-06-08 | 2017-07-17 | Millennium Pharmaceuticals, Inc. | Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer |
-
2007
- 2007-08-09 JP JP2009523844A patent/JP5725711B2/ja active Active
- 2007-08-09 AU AU2007284724A patent/AU2007284724B2/en not_active Ceased
- 2007-08-09 WO PCT/US2007/017716 patent/WO2008021183A2/en not_active Ceased
- 2007-08-09 US US11/891,213 patent/US9500656B2/en not_active Expired - Fee Related
- 2007-08-09 CA CA002660275A patent/CA2660275A1/en not_active Abandoned
- 2007-08-09 EP EP07836670A patent/EP2046973A4/en not_active Ceased
- 2007-08-09 MX MX2009001489A patent/MX2009001489A/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010500565A5 (enExample) | ||
| Fredsøe et al. | Diagnostic and prognostic microRNA biomarkers for prostate cancer in cell-free urine | |
| Bratman et al. | Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab | |
| Zhou et al. | Construction of an immune-related six-lncRNA signature to predict the outcomes, immune cell infiltration, and immunotherapy response in patients with hepatocellular carcinoma | |
| Mordente et al. | Cancer biomarkers discovery and validation: state of the art, problems and future perspectives | |
| Pan et al. | m5C-related lncRNAs predict overall survival of patients and regulate the tumor immune microenvironment in lung adenocarcinoma | |
| Fredsøe et al. | A five‐microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell‐free urine | |
| Che et al. | Evaluation of genetic risk score models in the presence of interaction and linkage disequilibrium | |
| CA2958801A1 (en) | Methods and materials for assessing homologous recombination deficiency | |
| Xu-Welliver et al. | Blood-based biomarkers in lung cancer: prognosis and treatment decisions | |
| Wang et al. | Identification of metastasis-related genes for predicting prostate cancer diagnosis, metastasis and immunotherapy drug candidates using machine learning approaches | |
| Schena et al. | DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients | |
| JP2017503527A5 (enExample) | ||
| JP2008544223A5 (enExample) | ||
| Kim et al. | Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma | |
| ES2882875T3 (es) | Método de pronóstico y predicción de la recurrencia del cáncer de mama, marcadores empleados en el mismo y kit del mismo | |
| Kim et al. | Upgrading of Gleason score and prostate volume: a clinicopathological analysis. | |
| WO2011133949A3 (en) | Genetic risk analysis in reward deficiency syndrome | |
| Fredsøe et al. | Independent validation of a diagnostic noninvasive 3-MicroRNA ratio model (uCaP) for prostate cancer in cell-free urine | |
| Wilson et al. | Breast cancer histopathology is predictive of low‐risk Oncotype Dx recurrence score | |
| Vendrell et al. | Evaluating ZNF217 mRNA expression levels as a predictor of response to endocrine therapy in ER+ breast cancer | |
| Vaezi et al. | ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer | |
| ES2914727T3 (es) | Algoritmos y métodos para evaluar los criterios clínicos tardíos en el cáncer de próstata | |
| Nam et al. | Identification of a novel MicroRNA panel associated with metastasis following radical prostatectomy for prostate cancer | |
| Ru et al. | Biomarkers for prognosis and treatment selection in advanced bladder cancer patients |